Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase 1 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Melanoma 53Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 32Neoplasms 29Neoplasm Metastasis 24Colorectal Neoplasms 21Carcinoma, Hepatocellular 21Squamous Cell Carcinoma of Head and Neck 18Stomach Neoplasms 16Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Small Cell Lung Carcinoma 11Pancreatic Neoplasms 11Lung Neoplasms 11Hodgkin Disease 11Carcinoma, Transitional Cell 10Advanced Cancer 9Sarcoma 8Recurrence 8Head and Neck Neoplasms 8Solid Tumor 7Prostatic Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Carcinoma, Merkel Cell 6Breast Neoplasms 6Mesothelioma 5Glioblastoma 5

Interventions

Gemcitabine 13Cisplatin 10pembrolizumab 7Oxaliplatin 5Leucovorin 5Fluorouracil 5durvalumab 4Paclitaxel 4Nivolumab 3Injections 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Docetaxel 2Cetuximab 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1surufatinib 1spartalizumab 1silmitasertib 1regorafenib 1pertuzumab 1manganese chloride 1lenvatinib 1irinotecan sucrosofate 1folfirinox 1devimistat 1derazantinib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Biliary Tract Neoplasms × Nivolumab × Clear all
NCT03785873 2026-02-13

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

University of Michigan Rogel Cancer Center

Phase 1/2 Completed
34 enrolled 13 charts
Gastrointestinal

Biliary Tract Neoplasms

NCT04278144 2025-09-15

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Bolt Biotherapeutics, Inc.

Phase 1/2 Terminated
175 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03311789 2017-10-17

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Chinese PLA General Hospital

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡